RxDoctor Payments Data

Jeffrey Carlin, MD

Rheumatology · Seattle, WANPI 1932218948

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $8,835 of the $10,937 with a category attached, or 80.8%. Johnson & Johnson accounts for 94.7% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $8,616 and has fallen 73.5% since, to $2,280 in 2025.

$10,937in general payments, 2019–2025

Across 17 payments — averaging $643.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$10K
  • Novartis$538
  • Sobi, Inc$22
  • GSK$19
$214,473in research payments, 2019–2025

Across 34 payments — averaging $6308.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boehringer Ingelheim$90K
  • AbbVie$28K
  • E.r. Squibb & Sons, L.L.C.$25K
  • Sanofi US Services Inc.$20K
  • Kadmon Corporation LLC$16K
  • Eli Lilly$16K
  • plus $19K from 4 others

What the payments were for

  • Consulting fees$8,83581%
  • Travel & lodging$1,65315%
  • Food & beverage$4494%

General payments by program year

19
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson13$10,358
Novartis2$538
Sobi, Inc1$22
GSK1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,937 in reported general payments places this provider in the 85th percentile of 157 rheumatology providers in Washington.

See all rheumatology providers in Washington

Medicare billing

Part B allowed, 2024
$2,456
Medicare patients
14
Services billed
24

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other rheumatology in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →